Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

by Jane Bayani, Cindy Q. Yao, Mary Anne Quintayo, Fu Yan, Syed Haider, Alister D’Costa, Cassandra L. Brookes, Cornelis J. H. van de Velde, Annette Hasenburg, Dirk G. Kieback, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel Rea, Paul C. Boutros, John M. S. Bartlett
Published 2017-02-01

Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

by John M. S. Bartlett, Jane Bayani, Elizabeth Kornaga, Keying Xu, Greg R. Pond, Tammy Piper, Elizabeth Mallon, Cindy Q. Yao, Paul C. Boutros, Annette Hasenburg, J. A. Dunn, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Cornelis J. H. van de Velde, Robert C. Stein, Daniel Rea
Published 2021-07-01

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

by Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn
Published 2020-08-01